259 related articles for article (PubMed ID: 22984577)
1. NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells.
Siegel D; Kepa JK; Ross D
PLoS One; 2012; 7(9):e44861. PubMed ID: 22984577
[TBL] [Abstract][Full Text] [Related]
2. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
[TBL] [Abstract][Full Text] [Related]
4. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
5. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
Siegel D; Franklin WA; Ross D
Clin Cancer Res; 1998 Sep; 4(9):2065-70. PubMed ID: 9748120
[TBL] [Abstract][Full Text] [Related]
7. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
8. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger.
Zhu H; Jia Z; Mahaney JE; Ross D; Misra HP; Trush MA; Li Y
Cardiovasc Toxicol; 2007; 7(3):202-11. PubMed ID: 17901563
[TBL] [Abstract][Full Text] [Related]
9. NAD(P)H: quinone oxidoreductase 1 expression in human bone marrow endothelial cells.
Siegel D; Ryder J; Ross D
Toxicol Lett; 2001 Dec; 125(1-3):93-8. PubMed ID: 11701227
[TBL] [Abstract][Full Text] [Related]
10. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.
Asher G; Dym O; Tsvetkov P; Adler J; Shaul Y
Biochemistry; 2006 May; 45(20):6372-8. PubMed ID: 16700548
[TBL] [Abstract][Full Text] [Related]
11. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems.
Anwar A; Dehn D; Siegel D; Kepa JK; Tang LJ; Pietenpol JA; Ross D
J Biol Chem; 2003 Mar; 278(12):10368-73. PubMed ID: 12529318
[TBL] [Abstract][Full Text] [Related]
12. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
13. Redox modulation of NQO1.
Siegel D; Dehn DD; Bokatzian SS; Quinn K; Backos DS; Di Francesco A; Bernier M; Reisdorph N; de Cabo R; Ross D
PLoS One; 2018; 13(1):e0190717. PubMed ID: 29298345
[TBL] [Abstract][Full Text] [Related]
14. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones.
Joseph P; Jaiswal AK
Br J Cancer; 1998 Mar; 77(5):709-19. PubMed ID: 9514048
[TBL] [Abstract][Full Text] [Related]
15. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.
Dinkova-Kostova AT; Talalay P
Arch Biochem Biophys; 2010 Sep; 501(1):116-23. PubMed ID: 20361926
[TBL] [Abstract][Full Text] [Related]
16. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
17. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
Asher G; Lotem J; Tsvetkov P; Reiss V; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15065-70. PubMed ID: 14634213
[TBL] [Abstract][Full Text] [Related]
18. Implications of NQO1 in cancer therapy.
Oh ET; Park HJ
BMB Rep; 2015 Nov; 48(11):609-17. PubMed ID: 26424559
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and genetic analysis of NAD(P)H:quinone oxidoreductase 1 (NQO1).
Siegel D; Kepa JK; Ross D
Curr Protoc Toxicol; 2007; Chapter 4():Unit4.22. PubMed ID: 23045144
[TBL] [Abstract][Full Text] [Related]
20. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]